Hypoxen 250 mg 30 capsules
Actovegin 200 mg 50 tablets
Prednisolone 5mg 100 tablets
Sialis 5 mg 14 tablets
Tamiflu 75 mg 10 capsules
Plaquenil 200 mg 60 tablets
Champix 1 mg 112 tablets
Ingavirin 90 mg 10 capsues
Ovestin 2 mg 30 tablets
Ovestin Vaginal cream 15g
Macmiror 200 mg 20 tablets
Ventolin nebula 20 ampoules
- Antibacterial medication
- Antifungal medication
- Antiviral Medication
- Cardiovascular medication
- different medication
- Hormonal medication
- Immunosuppressants and immunomodulating medications
- Nervous system
- Pain relievers and anti-inflammatory
- Respiratory system
- Treatment of diseases of the liver and gastrointestinal tract
- Treatment of sensory organs, eyesight and hearing
- Urogenital system
Piracetam 800 mg 30 tablets
De-Nol 120mg 112 tablets
De-Nol 120mg 56 tablets
De-Nol 120mg 32 tablets
finasteride 5mg 30 tablets
Itrazole 100 mg 42 capsules
furasol 15 sachets of 100 mg
Triacort OINTMENT 0.1% 10G
Urseptia 200 mg 20 capsules
Minolexin 50 mg 20 capsules
Immard 200 mg 30 tablets
Adenuric 120 mg 28 tablets
Vasobral 30 tablets
Mexidol 125 mg 50 tablets
Mirapex 1 mg 30 tablets
Novo-passit 10 tablets
Novo-passit 60 tablets
Persen night 20 capsules
Persen night 40 capsules
Enerion 200 mg 20 tablets
Mirapex 0.25 mg 30 tablets
Cinnarizine 25 mg 50 tablets
Ginos 40 mg 30 tablets
Phezam 400/25 mg 60 Capsules
Picamilon 50 mg 30 tablets
Midantan 100 mg 100 tablets
Baclosan 10 mg 50 tablets
Afobazol 10 mg 60 tablets
Donormil 30 tablets
Stugeron 25mg 50 tablets
betaserc 24 mg 20 tablets
Trileptal 150 mg 50 tablets
Relenza
Manufacturer: GlaxoSmithKline
Country of origin: France
General description: Antiviral drug
pharmachologic effect
Antiviral drug, a strong and highly selective inhibitor of neuraminidase (a surface enzyme of the influenza virus). Viral neuraminidase provides the release of viral particles from the infected cell and can accelerate the penetration of the virus through the mucosal barrier to the surface of epithelial cells, thereby ensuring the infection of other cells in the airways. The inhibitory activity of zanamivir is shown both in vitro and in vivo and includes all 9 subtypes of neuraminidase of influenza viruses, incl. circulating and virulent for different species. Half of the inhibitory concentration (IC50) for strains of virus A and B is from 0.09 to 95.2 pM.
Replication of the influenza virus is limited to the cells of the superficial epithelium of the respiratory tract. Zanamivir acts in the extracellular space, reducing the reproduction of both types of influenza A and B virus and preventing the release of viral particles from the cells of the superficial epithelium of the respiratory tract.
The efficacy of zanamivir for inhalation has been confirmed in controlled clinical trials. The use of zanamavir as a therapy for acute infections caused by the influenza virus led to a decrease in the release of the virus (compared to placebo). The development of resistance to zanamivir in individuals with normal immunity is not recorded.
Clinical efficacy and safety
The use of zanamivir, a powder for inhalation dosed, in healthy people at risk (usually in contact with the sick), in doses used in the treatment of influenza, facilitates symptomatology and shortens the duration of the disease. A combined analysis of the results of phase III studies showed that the median time to alleviate the symptoms of the disease was reduced to 1.5 days in patients in the zanamivir group compared to patients in the placebo group (p <0.001). The number of complications decreased in the group of zanamivir 171/769 (22%) compared with placebo 208/711 (29%) and the relative risk was: 0.77; (95% CI: 0.65-0.92, p = 0.004).
The use of antibiotics for the treatment of complications after influenza also decreased from 136/711 (19%) in the placebo group to 110/769 (14%) in the zanamivir group (relative risk: 0.76; 95% CI: 0.60-0.95; p = 0.021) .
The optimal efficacy of zanamivir was shown in the case of starting treatment as soon as possible after the appearance of the first symptoms of the disease. It has been shown that zanamivir is also effective as a means of preventing influenza in children older than 5 years and in adults. The percentage of effective protection is 67-79% compared with placebo and 56-61% compared to active control.
Indications
- Treatment of infection caused by the influenza A and B virus in children older than 5 years and adults;
- Prevention of infection caused by the influenza virus type A and B, in children older than 5 years and adults.


.